Interfyl is a decellularized human placental connective tissue matrix (CTM) to be used for the replacement or supplementation of damaged or inadequate integumental tissue.
For more information please contact Celularity at 1-844-963-2273
Available in flowable and particulate form in units of weight ranging from 45mg to 275mg to meet a variety of application needs
0.3 mL Flowable
Product code: HCTM030
0.6 mL Flowable
Product code: HCTM060
100 mg Flowable
Product code: HCTM001
1 mL Flowable
Product code: HCTM010
1.5 mL Flowable
Product code: HCTM015
50 mg Particulate
Product code: HCTM050
100 mg Particulate
Product code: HCTM100
WE PUT SAFETY AT THE TOP OF THE LIST
Interfyl® tissue procurement and processing practices meet high safety standards.
Tissue used in processing Interfyl:
- Has been procured, processed, and tested in accordance with standards established by the American Association of Blood Banks (AABB) and the United States Food and Drug Administration (FDA)
- Passed safety testing for cytotoxicity, hemolysis, irritation, endotoxins, and pyrogenicity
- Utilizes a barcode tracking system for optimal safety monitoring and to enhance patient and practitioner confidence
Donor screening and testing
- Maternal health screening, including social history
- Family medical history
- Lab testing on donor blood and afterbirth for infectious diseases, including:
- HIV 1/2 Antibodies
- HIV NAT
- HTLV I/II Antibodies
- West Nile Virus NAT
- CMV Antibodies
- Hepatitis C Antibody
- Hepatitis C NAT
- Hepatitis B Core Antibody
- Hepatitis B Surface Antigen
- Hepatitis B NAT
- Antibody Screen
- Syphilis Screening Assay
- CMV Antibody
- Trypanosoma cruzi (Chagas) Antibody
Celularity adheres to high standards of ethical practice and transparency in all aspects of our operations. Celularity is registered with the FDA as a tissue establishment and accredited by the AABB.
Indications for Use
(For surgical indications)
lnterfyl is intended for use as the replacement or supplementation of damaged or inadequate integumental tissue. Indications include, but are not limited to, treatment of soft tissue voids, correction of soft tissue defects, soft tissue augmentation during repair of dehisced or complicated surgical closures and repair of small surgical defects resulting from either medical or surgical conditions including those with exposed vital structures (bone, tendon, ligament, or nerve).
(For wound indications)
lnterfyl is intended for use as the replacement or supplementation of damaged or inadequate integumental tissue. Indications include, but are not limited to: augmentation of deficient/inadequate soft tissue and treatment of deep dermal wounds; surgical wounds; soft tissue voids as a result of tunneling wounds, fistula tracts, or dermal undermining-including those with exposed vital structures (bone, tendon, ligament, or nerve).
Contraindications, Warnings, and Precautions
Interfyl should not be used in clinically infected sites. If a recipient had an adverse reaction related to previous use of Interfyl, do not re-apply.
Do not use lnterfyl for intravenous, intra-arterial, intra-ocular, or intrathecal applications.
lnterfyl must be used prior to the expiration date on the product pouch. Once opened, lnterfyl must be used within two hours or discarded per institutional procedures. The contents are sterile if the vial/syringe (container) is unopened and undamaged. Do not sterilize.
For product information, product complaints, or adverse reaction reporting, call 1-844-963-2273.
Please refer to the Interfyl Package Insert for complete product information.